Systematic review / meta-analysis / 2024
Phentermine-topiramate and GLP-1 receptor agonists were the most effective drugs for weight loss compared to lifestyle modification alone.
A network meta-analysis of 132 randomized controlled trials evaluated weight-lowering drugs in 48,209 adults with overweight and obesity compared to lifestyle modification alone. Phentermine-topiramate showed the highest efficacy for ≥5% weight reduction (OR 8.02, 95% CI 5.24 to 12.27; MD -7.98%, 95% CI -9.27 to -6.69), followed by GLP-1 receptor agonists (OR 6.33, 95% CI 5.00 to 8.00; MD -5.79%, 95% CI -6.34 to -5.25). Increased adverse events leading to drug discontinuation were noted for naltrexone-bupropion, phentermine-topiramate, GLP-1 receptor agonists, and orlistat. In a post-hoc analysis, semaglutide demonstrated greater weight loss benefits (OR 9.82; MD -11.40%) with similar adverse event risk.
- Study type
- Systematic review and network meta-analysis of RCTs
- Who was studied
- 48,209 adults with overweight and obesity across 132 trials
- What was measured
- Weight reduction (≥5% weight loss, percentage bodyweight change) and adverse events leading to discontinuation
THE PAPER
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J, Chen Z, Xu S, Shen Y, Ge L, Sun F, Li L, Yu J, Nong K, Zou X, Zhu S, Wang C, Zhang S, Qiao Z, Jian Z, Li Y, Zhang X, Chen K, Qu F, Wu Y, He Y, Tian H, Li S. Lancet, 2024.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.